ISRCTN12698107已完成不适用
A multicentre phase II randomised dose escalation study comparing two schedules of hypo-fractionated radiotherapy: 36 Gy in 6# over two weeks (treatment arm) and 20 Gy in 5# over one week (standard arm)
HS Greater Glasgow & Clyde0 个研究点目标入组 112 人开始时间: 2015年11月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histological and/or MDT diagnosis of MPM
- •2. Performance status 0-2 (ECOG)
- •3. Predicted life expectancy of >12 weeks
- •4. CT scan within 8 weeks of radiotherapy
- •5. Worst Pain =4/10 (0-10 Numerical Rating Scale) after optimisation of analgesics
- •6. Ability to provide written informed consent prior to participating in the trial and any trial related procedures being performed
- •7. Willingness to comply with scheduled visits, treatment plans and laboratory tests and other study procedures
- •8. Patients must have a radiotherapy plan compatible with both the standard arm (20 Gy in 5 fractions) and treatment arm (30-36 Gy in 5-6 fractions)
排除标准
- •1. Patients who have received anti-cancer therapy within the 4 weeks prior to study entry that is likely to alter pain at the index site during the duration of the study
- •2. Patients who are planned to have further anti-cancer therapy within 6 weeks post radiotherapy treatment
- •3. Psychotic disorders or cognitive impairment
- •4. Co-existing lung tumours at the time of study entry
- •5. Pregnant or breastfeeding
- •6. Patients of child-bearing potential, who are unwilling to use 2 effective methods of contraception
研究者
相似试验
撤回
1 期
To explore the tolerance and activity of increasing doses of Panobinostat when given in combination with Bortezomib, Cyclophosphamide and Dexamethasone to patients with symptomatic Multiple Myeloma who have had no previous treatment.Multiple Myeloma (Treatment Naive)Cancer - MyelomaACTRN12612000779875orth Shore Haematology Clinical Trial Unit37
进行中（未招募）
1 期
Glioblastoma photodynamic therapyGlioblastomaEUCTR2019-004796-40-BECHU de Lille21
进行中（未招募）
1 期
Glioblastoma photodynamic therapyGlioblastomaEUCTR2019-004796-40-FRCHU de Lille21
进行中（未招募）
不适用
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL and other hematological malignancies - NACML in accelerated or chronic phase or blast crisis, relapsed/refractory Ph+ ALL, systemic mastocytosis, or hypereosinophilic syndrome.MedDRA version: 14.0Level: LLTClassification code 10009700Term: CMLSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-001483-51-GBovartis Pharma Services AG955
进行中（未招募）
不适用
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL or other hematologic malignancies - NAEUCTR2004-001483-51-FIovartis Pharma AG955